Table of Contents
Bisphosphonate Bone Metastases Trials Proportion of Patients With Any SRE§ (12, 010)
Bisphosphonate Bone Metastases Trials Demographic and Prognostic Variables (12, 010)
Bisphosphonate Bone Metastases Trials Proportion of Patients With Pathologic Fractures§ (12, 010)
Patients With Any SRE up to End-of-Core by Race (010, 011, 039)
ZOMETA® Efficacy in Bone Metastases
Solid Tumors – PC/BC Antineoplastic Therapies After Start of Study Drug (011)
Breast Cancer and Multiple Myeloma Frequency Distribution of Antineoplastic Regimens (010) (1)
Breast Cancer and Multiple Myeloma Frequency Distribution of Antineoplastic Regimens (010) (2)
Solid Tumors – PC/BC Frequency Distribution of Antineoplastic Regimens (011)
Solid Tumors –PC/BC Time to First SRE Deaths and Dropouts Considered SREs (011)
Breast Cancer and Multiple Myeloma Time to First SRE Deaths and Dropouts Considered SREs (010)
Prostate Cancer Time to First SRE Deaths and Dropouts Considered SREs (039)
Cumulative Incidence Rate of SRE All Patients§ (039)
Prostate Cancer Median Serum PSA Level (Observed) (039)
Prostate Cancer Total Number of SREs (039)
Cumulative Incidence Rate of SRE All Patients§ (011)
Solid Tumors –PC/BC Total Number of SREs (011)
Breast Cancer and Multiple Myeloma Total Number of SREs (010)
|